Quantcast

Latest Sipuleucel-T Stories

2011-06-29 19:04:00

SEATTLE, June 29, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S.

2011-06-23 15:30:00

NEW YORK, June 23, 2011 /PRNewswire/ -- For years, researchers have dreamed of curing prostate cancer with targeted drugs that could modulate the body's own immune system to attack and destroy malignant cancer cells.

2011-06-16 05:00:00

SEATTLE, June 16, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the NASDAQ OMX 26th Investor Program in London on June 21, 2011 at 9:30 a.m. GMT (4:30 a.m.

2011-06-13 17:32:00

SEATTLE, June 13, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., President and Chief Executive Officer received the Ernst & Young Entrepreneur Of The Year(®) 2011 Pacific Northwest Award in the Emerging Sciences category. Dr.

2011-06-03 12:24:15

Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it.

2011-05-20 05:00:00

SEATTLE, May 20, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences: ThinkEquity Annual Healthcare Conference in New York City, NY on May 25, 2011 at 1:00 p.m.

2011-05-19 07:15:00

AUBURNDALE, Mass., May 19, 2011 /PRNewswire/ -- Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S.

2011-05-18 17:00:00

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 2011 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

2011-05-18 17:00:00

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced three abstracts accepted for poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) and the clinical trial of DN24-02 in bladder cancer at the upcoming American Society for Clinical Oncology annual meeting in Chicago, Illinois.

2011-05-16 13:50:00

MAYWOOD, N.J., May 16, 2011 /PRNewswire/ -- New Jersey Center for Prostate Cancer & Urology is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.


Word of the Day
bawbee
  • A coin originally worth six pennies Scots, and later three; held equivalent to an English halfpenny.
  • (in plural) Money; cash.
Related